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coBACKGROUND Clinical trials have demonstrated beneﬁt for cardiac resynchronization therapy (CRT) and implantable
cardioverter-deﬁbrillator (ICD) therapies in patients with heart failure with reduced ejection fraction (HFrEF); yet,
questions have been raised with regard to the beneﬁt of device therapy for minorities.
OBJECTIVES The purpose of this study was to determine the clinical effectiveness of CRT and ICD therapies as a
function of race/ethnicity in outpatients with HFrEF (ejection fraction #35%).
METHODS Data from IMPROVE HF (Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the
Outpatient Setting) were analyzed by device status and race/ethnicity among guideline-eligible patients for mortality at
24 months. Multivariate Generalized Estimating Equations analyses were conducted, adjusting for patient and practice
characteristics.
RESULTS The ICD/cardiac resynchronization deﬁbrillator (CRT-D)–eligible cohort (n¼ 7,748) included 3,391 (44%) non-
Hispanic white, 719 (9%) non-Hispanic black, and 3,638 (47%) other racial/ethnic minorities or race-not-documented
patients. The cardiac resynchronization pacemaker (CRT-P)/CRT-D–eligible cohort (n ¼ 1,188) included 596 (50%)
non-Hispanic white, 99 (8%) non-Hispanic black, and 493 (41%) other/not-documented patients. There was clinical
beneﬁt associated with ICD/CRT-D therapy (adjusted odds ratio: 0.64, 95% conﬁdence interval: 0.52 to 0.79, p ¼
0.0002 for 24-month mortality), which was of similar proportion in white, black, and other minority/not-documented
patients (device–race/ethnicity interaction p ¼ 0.7861). For CRT-P/CRT-D therapy, there were also associated mortality
beneﬁts (adjusted odds ratio: 0.55, 95% conﬁdence interval: 0.33 to 0.91, p ¼ 0.0222), and the device–race/ethnicity
interaction was not signiﬁcant (p ¼ 0.5413).
CONCLUSIONS The use of guideline-directed CRT and ICD therapy was associated with reduced 24-month mortality
without signiﬁcant interaction by racial/ethnic group. Device therapies should be offered to eligible heart failure patients,
without modiﬁcation based on race/ethnicity. (J Am Coll Cardiol 2014;64:797–807) © 2014 by the American College of
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CI = conﬁdence interval
CRT = cardiac
resynchronization therapy
CRT-D = cardiac
resynchronization deﬁbrillator
CRT-P = cardiac
resynchronization pacemaker
GEE = generalized estimating
equations
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
ICD = implantable
cardioverter-deﬁbrillator
LVEF = left ventricular ejection
fraction
OR = odds ratio
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798I mplantable cardioverter-deﬁbrillators(ICDs) and cardiac resynchronizationtherapy (CRT) are shown to improve
clinical outcomes in selected patients with
heart failure with reduced ejection fraction
(HFrEF) in multiple clinical trials (1–5).
For appropriate patients, guidelines endorse
Class I recommendations for device thera-SEE PAGE 808pies in the primary prevention of sudden
cardiac death and CRT for functional im-
provement and risk reduction of heart failure
(HF) events regardless of race (6,7). However,
the under-representation of racial/ethnic mi-
norities in prior trials has raised the question
as to whether the beneﬁts extend to these
patient populations (8). Although analysisof the SCD-HeFT (Sudden Cardiac Death in Heart
Failure Trial) has shown similar event rates and
mortality beneﬁt for primary prevention in African
Americans, uncertainty has remained regarding
whether these ﬁndings can be generalized to real-
world clinical practice (9). Furthermore, multiple
studies have highlighted the disparate use of device
therapies for racial/ethnic minorities and the complex
combination of systemic factors that contribute to
healthcare disparities (10–12). Although some recent
studies suggest that the racial/ethnicity gaps for
African Americans and Hispanics may be narrowing,
opportunities to improve use in eligible patients
remain (13,14). The uncertainty of whether minority
groups derive similar beneﬁt from device therapiesd research honoraria from Medtronic, Inc. and St. Jude Medica
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practice.
The IMPROVE HF (Registry to Improve the Use
of Evidence-Based Heart Failure Therapies in the
Outpatient Setting) cohort provides an opportunity
to evaluate the beneﬁt of device therapy in real-
world clinical practice among minority outpatients
with HF. The purpose of this study was to determine
the clinical effectiveness of cardiac resynchroni-
zation deﬁbrillator (CRT-D) and ICD therapy as
a function of racial/ethnic classiﬁcation of out-
patients with HFrEF (left ventricular ejection fraction
[LVEF] #35%).
METHODS
This pre-speciﬁed analysis of the IMPROVE HF reg-
istry is a prospective, observational cohort study of
15,177 patients diagnosed with HF (or prior myocar-
dial infarction [MI]) and reduced LVEF being treated
at outpatient cardiology (including multispecialty)
practices. The primary objective of the IMPROVE
HF registry was to evaluate the effects of a practice-
speciﬁc performance improvement initiative on
adherence to guideline-recommended therapies. The
methods and primary results of the IMPROVE HF
registry were previously reported (15).
Brieﬂy, community and university outpatient
cardiology/multispecialty practices were invited to
participate. All sites were required to obtain institu-
tional review board approval or waivers prior to
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799fraction who were >18 years of age at the time of
the most recent ofﬁce visit were eligible for enroll-
ment. Study participants were required to have an
LVEF #35%, as measured by the most recent echo-
cardiogram, nuclear multigated acquisition (scan,
contrast ventriculogram, cardiac magnetic resonance,
or qualitative assessment of left ventricular func-
tion indicative of moderate-to-severe dysfunction).
Patients who met the guideline-speciﬁed eligibility
criteria for each individual therapy, with no contra-
indications, intolerance, or other documented rea-
sons for not receiving the therapy, were eligible for
inclusion in the analyses for that measure. For
this analysis, study participants were required to
be eligible for ICD/CRT-D or CRT-P/CRT-D therapy.
Eligibility for ICD therapy was based on a primary
prevention indication, and CRT eligibility criteria
were based on the American College of Cardiology/
American Heart Association/Heart Rhythm Society
guidelines from 2005, 2008, and 2009 (16–19). Docu-
mentation of QRS duration and New York Heart As-
sociation (NYHA) functional class consistent with
guideline speciﬁcations was required to be consid-
ered eligible for ICD/CRT-D or CRT-P/CRT-D therapy;
thus, only patients with QRS duration documented
were included in analyses for CRT-P/CRT-D therapy.
The primary endpoint was vital status (alive/dead)
at 24-month follow-up.
Patients were not eligible to participate in the
IMPROVE HF registry if they were not expected to
survive for 12 months due to medical conditions other
than HF, or had undergone heart transplant surgery.
NYHA functional class IV was an exclusion criterion
for ICD-only therapy.
Medical records of eligible patients were selected
at random to yield an average of approximately 90
patients per participating practice. A total of 34
trained chart-review specialists extracted baseline
demographics, clinical characteristics, and diagnostic
and laboratory ﬁndings from patient charts. Patient
race and ethnicity were collected to evaluate sub-
group differences. The administrative and/or medical
staff at participating practices were instructed to
record patients’ self-assigned race/ethnicity. Each
case report form included the following options
for race: American Indian or Alaskan Native, Asian,
black or African American, Native Hawaiian or
Paciﬁc Islander, white, or undocumented. Ethnicity
was recorded as Hispanic (yes/no) or not docu-
mented. A rigorous methodology was utilized in the
IMPROVE HF study design to ensure the quality and
accuracy of data. Data collection was centrally per-
formed by Outcome Sciences Inc. (Cambridge,
Massachusetts). The average inter-rater reliabilitybetween chart reviewers was 0.82 (k statistic). An
average of 1.7 automated data quality checks were
performed for each data ﬁeld to ensure that all
values met pre-speciﬁed ranges, formats, and units.
Source data veriﬁcation was randomly performed
for 20% of the entire patient sample for 10%
of participating practices. Additionally, monthly
data quality reports were provided to the steering
committee.
STATISTICAL ANALYSIS. Descriptive statistics for
patient baseline characteristics and practice charac-
teristics by race were calculated within the ICD/
CRT-D and CRT-P/CRT-D cohorts. This included
mean and SD for continuous variables and frequency
and percentage for categorical variables.
Generalized Estimating Equations (GEE) modeling
was used to estimate unadjusted and adjusted rela-
tionships between device treatment and patient-level
mortality in the ﬁrst 24 months and to investigate
if the clinical effectiveness of ICD/CRT-D or CRT-P/
CRT-D therapy in improving 24-month mortality
would vary by race/ethnic group. An exchangeable
within-practice correlation matrix was used in the
modeling to account for correlation of patients from
the same cardiology practice. The clinical bene-
ﬁt of being treated with devices at baseline on
24-month mortality was evaluated using univar-
iate GEE models for each cohort and then for
race/ethnicity subgroups: non-Hispanic white; non-
Hispanic black; and other race, Hispanic ethnicity,
or race/ethnicity undocumented within each cohort.
In each model, vital status (dead/alive) at 24 months
was the outcome and treatment with the device
at baseline (yes/no) was the predictor. Univariate
analysis produced the unadjusted odds ratio (OR) of
death and its 95% conﬁdence interval (CI) for device
therapy per cohort and per race/ethnicity-speciﬁc
subcohort. Furthermore, multivariate GEE models
were performed in ICD/CRT-D and CRT-P/CRT-D
cohorts separately to determine if the clinical effec-
tiveness of device therapy on 24-month mortality
would be different between patients classiﬁed as non-
Hispanic white; non-Hispanic black; and other race
group, Hispanic ethnicity, or race/ethnicity undocu-
mented, controlling for other baseline patient and
practice characteristics. We ﬁrst screened the char-
acteristics through univariate GEE analysis and
included those with p values #0.10 as the covariates
for device therapy in initial multivariate GEE models.
We then eliminated the covariates with p values
$0.05 using backward selection and added race/
ethnicity (if it was not in the reduced models yet)
and race/ethnicity by device interaction terms into
the reduced models. The adjusted OR, 95% CI, and
15,177 patients in
IMPROVE-HF cohort 
11,621 patients with
documented follow up
1023 patients included 
in CRT-P/CRT-D
analysis
754 patients with
early crossover
6,994 patients 
included in ICD/CRT-D
analysis
165 patients with
early crossover
5628 patients in 
ICD only analysis
1366 patients with 
CRT-D in place at
baseline
7,748 patients eligible 
for ICD/CRT-D
1,188 patients eligible 
for CRT-P/CRT-D
3,556 without 
documented vital status 
at 24-month follow up
FIGURE 1 Patient Enrollment and Study Eligibility
Flow diagram of patient enrollment and study eligibility by
device type. CRT-D ¼ cardiac resynchronization deﬁbrillator;
CRT-P ¼ cardiac resynchronization pacemaker; ICD ¼ implant-
able cardioverter-deﬁbrillator; IMPROVE HF ¼ Registry to
Improve the Use of Evidence-Based Heart Failure Therapies in
the Outpatient Setting.
Ziaeian et al. J A C C V O L . 6 4 , N O . 8 , 2 0 1 4
Race/Ethnicity, Device Therapy, and Mortality A U G U S T 2 6 , 2 0 1 4 : 7 9 7 – 8 0 7
800p value for device therapy were reported, as well
as the p value for device by race/ethnicity interaction.
In sensitivity analyses, univariate and multivariate
GEE analyses also were conducted in the ICD-
only cohort. To verify the ﬁndings on interaction
effect, additional device by race/ethnicity interac-
tion testing was performed for each cohort by sub-
grouping the entire sample into non-Hispanic white
and black patients, which excluded other race and
race/ethnicity undocumented patients. Similarly, in-
teraction testing was performed on the patients
classiﬁed as non-Hispanic white and other race and
race/ethnicity undocumented, which excluded non-
Hispanic black patients. As part of a post-hoc anal-
ysis, given our observational sample size and OR
estimated from the multivariate GEE analysis, we
estimate a 75% power in the ICD/CRT-D cohort, a
41% power in the ICD-only cohort, and 15% power in
the CRT-P/CRT-D cohort to detect a device by race/
ethnicity interaction at a signiﬁcance level of 0.05.
During the ﬁrst 12 months of the performance
initiative, some patients who were eligible for a
device, yet not treated at baseline, crossed over and
had the device implanted. The crossover patients
were included in the descriptive analysis of baseline
characteristics. However, they were excluded from all
of the GEE analyses to assess the pure relationship
between use of device therapy at baseline and vital
status at 24 months.
All statistical inference testing was 2-sided, with
results considered statistically signiﬁcant at p < 0.05.
Analyses were completed using SAS statistical soft-
ware version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
A total of 15,177 patients from 167 U.S. outpatient
cardiology practices were evaluated at baseline and
included in the longitudinal cohort. A median of 90
patient records per practice were entered. There was
documentation of vital status at the 24-month
follow-up in 11,621 (76.6%) patients. Of patients
with vital status data at follow-up, 7,748 were eligible
for ICD/CRT-D and 1,188 for CRT-P/CRT-D therapy
at baseline. During the ﬁrst 12 months of the per-
formance initiative, 754 ICD/CRT-D–eligible and
165 CRT-P/CRT-D–eligible patients who did not
have such devices at baseline had them implanted.
After excluding these early crossovers, this analysis
included a total of 6,994 patients from the ICD/CRT-D
cohort and 1,023 patients from the CRT-P/CRT-D
cohort (Fig. 1). In the analyses for the ICD-only
cohort, 1,366 patients who had CRT-D in place at
baseline were excluded from the 6,994 ICD/CRT-Dpatients, leaving 5,628 patients for these ICD-only
analyses.
Baseline patient and practice site characteristics
among the ICD/CRT-D–eligible cohort were stratiﬁed
by race/ethnicity and are listed in Tables 1 and 2. The
ICD/CRT-D–eligible cohort (n ¼ 7,748) patients were
44% (n ¼ 3,391) non-Hispanic white, 9% (n ¼ 719)
non-Hispanic black, and 47% (n ¼ 3,638) other race,
Hispanic ethnicity, or race/ethnicity undocumented.
Within the other race, Hispanic ethnicity, or race/
ethnicity undocumented cohort (n ¼ 3,638), the
patients were 3.9% (n ¼ 142) Hispanic, 0.4% (n ¼ 13)
non-Hispanic American Indian/Native American, 1.1%
(n ¼ 39) non-Hispanic Asian, 0.3% (n ¼ 9) non-
Hispanic Native Hawaiian/Other Paciﬁc Islander,
1.3% (n ¼ 48) other race/ethnicity, and 93% (n ¼
3,387) race/ethnicity undocumented. Notably, non-
Hispanic black patients were much younger, and the
proportion of them having HF attributed to ischemic
TABLE 1 Patient Characteristics of the ICD- or CRT-D–Eligible Cohort by Race/Ethnicity*
Non-Hispanic White
(n ¼ 3,391)
Non-Hispanic Black
(n ¼ 719)
Other Race, Hispanic
Ethnicity, or Not Documented
(n ¼ 3,638)
Age, yrs 69.9  12 59.4  14.9 69.7  12.6
Women 932 (27.5) 306 (42.6) 1,023 (28.1)
Insurance
Medicare 2,193 (64.7) 364 (50.6) 2,218 (61)
Other 1,023 (30.2) 317 (44.1) 1,146 (31.5)
Not documented 175 (5.2) 38 (5.3) 274 (7.5)
Ischemic heart failure 2,488 (73.4) 299 (41.6) 2,652 (72.9)
History of atrial ﬁbrillation 1,131 (33.4) 171 (23.8) 1,154 (31.7)
History of diabetes 1,198 (35.3) 299 (41.6) 1,240 (34.1)
History of hypertension 2,165 (63.8) 554 (77.1) 2,143 (58.9)
Previous myocardial infarction 1,777 (52.4) 211 (29.3) 1,834 (50.4)
History of chronic obstructive pulmonary disease 713 (21) 90 (12.5) 568 (15.6)
History of coronary artery bypass grafting 1,250 (36.9) 92 (12.8) 1,255 (34.5)
History of percutaneous coronary intervention 1,051 (31) 116 (16.1) 998 (27.4)
History of peripheral vascular disease 447 (13.2) 72 (10) 425 (11.7)
NYHA functional class
I and II 2,372 (69.9) 454 (63.1) 2,600 (71.5)
III and IV 1,019 (30.1) 265 (36.9) 1,038 (28.5)
Left ventricular ejection fraction, % 24.8  6.8 23.1  7.3 25.1  6.8
Systolic blood pressure, mm Hg 119.3  18.4 121.2  19.7 119.4  18.5
Diastolic blood pressure, mm Hg 69.3  10.7 73  12.2 69.4  11
Heart rate at rest, beats/min 72.1  11.1 74.6  12.6 71.7  11.1
Edema 725 (21.4) 171 (23.8) 717 (19.7)
Sodium, mEq/l 139.1  3.3 138.9  3.4 139.5  3.4
Serum urea nitrogen, mg/dl 26.2  14.4 23.5  16.4 25.9  14.4
Creatinine, mg/dl 1.4  0.7 1.6  1.2 1.4  0.7
Potassium, mEq/l 4.4  0.5 4.2  0.5 4.4  0.5
B-type natriuretic peptide, pg/ml 697.8  896.4 643  815.2 688.7  870.4
QRS duration, ms 135.8  38.4 123.5  35.3 131  37.2
QRS missing 997 (29.4) 184 (25.6) 1,231 (33.8)
QRS duration >120 ms 1,430 (42.2) 230 (32) 1,280 (35.2)
Values are mean  SD or n (%). *Early crossovers included.
CRT-D ¼ cardiac resynchronization deﬁbrillator; ICD ¼ implantable cardioverter-deﬁbrillator; NYHA ¼ New York Heart Association.
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801heart disease was 32% lower in absolute values
compared with non-Hispanic white patients and
patients in the other/undocumented race/ethnicity
group. The proportion of women among black pati-
ents was 15% higher in absolute values than the
proportion of women in the white and other or
race/ethnicity undocumented groups. Rates of hy-
pertension and diabetes were higher for black pati-
ents. The rates of prior MI, coronary artery bypass
graft surgery, percutaneous coronary intervention,
and atrial ﬁbrillation were much lower for black pati-
ents as compared with white patients and other
or race/ethnicity undocumented groups. A higher
proportion of black patients had NYHA functional
class III or IV. Black patients had the shortest QRS
duration and lowest B-type natriuretic peptides,
whereas white patients had the longest QRS duration
and largest B-type natriuretic peptide value. MeanLVEF, sodium, blood and urea nitrogen were similar
among the 3 groups. Of patients eligible for ICD/CRT-D
therapy, 1,810 of 3,391 (53%) non-Hispanic white, 362
of 719 (50%) non-Hispanic black, and 1,755 of 3,638
(48%) other race, Hispanic ethnicity, or race/ethnicity
undocumented patients had an ICD/CRT-D device in
place. Of patients eligible for CRT-P/CRT-D therapy,
228 of 596 (38%) non-Hispanic white, 38 of 99 (38%)
non-Hispanic black, and 182 of 493 (37%) other race,
Hispanic ethnicity, or race/ethnicity undocumented
patients had a CRT-P/CRT-D device in place.
The practice characteristics of the ICD/CRT-D–
eligible cohort are shown in Table 2. The majority
of the patients were from nonuniversity, nonteaching
(5,096 of 7,748, 66%) and nonmultispecialty clinics
(1,890 of 7,748, 24%). Less than 40% (2,757 of 7,748)
of patients had electronic medical health records.
The percentage of non-Hispanic black patients that
TABLE 2 Practice Characteristics of the ICD- or CRT-D–Eligible Cohort by Race/Ethnicity*
Non-Hispanic
White
(n ¼ 3,391)
Non-Hispanic
Black
(n ¼ 719)
Other Race,
Hispanic Ethnicity,
or Not Documented
(n ¼ 3,638)
Census region
South 1,374 (40.5) 378 (52.6) 1,370 (37.7)
West 384 (11.3) 66 (9.2) 616 (16.9)
Central 733 (21.6) 104 (14.5) 656 (18)
Northeast 900 (26.5) 171 (23.8) 996 (27.4)
Outpatient practice setting
Nonuniversity, nonteaching 2,182 (64.3) 299 (41.6) 2,615 (71.9)
Nonuniversity, teaching 880 (26) 208 (28.9) 802 (22)
University, teaching 329 (9.7) 212 (29.5) 221 (6.1)
Multispecialty 706 (20.8) 245 (34.1) 957 (26.3)
Electronic health record
Paper 1,647 (48.6) 403 (56.1) 1,466 (40.3)
Mixed 632 (18.6) 158 (22) 685 (18.8)
Electronic 1,112 (32.8) 158 (22) 1,487 (40.9)
Heart failure nurses
>1 1,412 (41.6) 259 (36) 1,655 (45.5)
#1 1,909 (56.3) 428 (59.5) 1,877 (51.6)
Missing 70 (2.1) 32 (4.5) 106 (2.9)
Number of electrophysiologists
in practice
1.6  1.7 2.1  1.7 2  2
Number of interventionalists
in practice
4.9  3.3 4.9  2.8 5.3  3.3
Number of heart failure clinics
in practice
1.5  0.5 1.3  0.5 1.5  0.5
Number of cardiologists
in practice
13.1  12.1 13.4  9.2 16.3  13.5
Values are n (%) or mean  SD. *Early crossovers included.
Abbreviations as in Table 1.
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802were treated at university-based teaching institu-
tions was much higher than that of the other 2
race/ethnicity-speciﬁc subgroups (Table 2).
Table 3 demonstrates 24-month mortality rates
and unadjusted/adjusted ORs for the ICD/CRT-
D–eligible cohort and race groups within the cohort.TABLE 3 Rates and Unadjusted and Adjusted Odds Ratios for 24-Mon
Subjects
ICD or CRT-D
at Baseline n
Mortality at
24 Months,
n (%)
Un
O
(
ICD/CRT-D eligible Yes 3,927 801 (20.4) 0.66
No 3,067 852 (27.8)
Non-Hispanic white Yes 1,810 371 (20.5) 0.65
No 1,294 365 (28.2)
Non-Hispanic black Yes 362 74 (20.4) 0.74
No 294 77 (26.2)
Other race, Hispanic ethnicity,
or not documented
Yes 1,755 356 (20.3) 0.66
No 1,479 410 (27.7)
*Interaction testing was repeated for subsets of the entire population: non-Hispa
ethnicity/undocumented. Variables used for adjustment are noted in the Results section
CI ¼ conﬁdence interval; other abbreviations as in Table 1.Study patients having ICD or CRT-D at baseline were
34% less likely to die at 24 months compared with
those who did not have a device at baseline (20.4%
vs. 27.8%, unadjusted OR: 0.66, 95% CI: 0.58 to 0.74,
p < 0.0001). On multivariate analysis controlling
for age; sex; race; heart failure etiology; comorbid
conditions including diabetes, myocardial infarction,
chronic obstructive pulmonary disease, and periph-
eral vascular disease; NYHA functional class; edema;
LVEF; systolic blood pressure; sodium; blood urea
nitrogen; and creatinine, these ﬁndings remained
signiﬁcant (adjusted OR: 0.64, 95% CI: 0.52 to 0.79,
p ¼ 0.0002). The test for device by race/ethnicity
interaction was not signiﬁcant (p ¼ 0.7861). The pro-
portional risk reductions were similar across each
of the race/ethnicity groups according to the multi-
variate GEE analysis. The overlapping of their 95%
CIs is consistent with the ﬁnding of nonsigniﬁcant
interaction between device and race/ethnicity. How-
ever, statistical signiﬁcance was not detected in all
individual race/ethnicity groups according to the
multivariate GEE analysis.
Table 4 demonstrates 24-month mortality rates
and unadjusted/adjusted ORs for the ICD-only cohort
and race/ethnicity groups within the cohort. Study
patients with baseline ICD therapy were less likely
to die at 2 years when compared with those without
ICD therapy (20.2% vs. 27.8%), and after multi-
variable analysis, this ﬁnding remained signiﬁcant
(adjusted OR: 0.72, 95% CI: 0.58 to 0.89, p ¼ 0.0046).
Again, the device by race/ethnicity interaction was
not signiﬁcant in this ICD-only cohort (p ¼ 0.8225).
Table 5 demonstrates 24-month mortality rates
and unadjusted/adjusted ORs for the CRT-P/CRT-
D–eligible cohort and race/ethnicity groups within the
cohort. Study patients with CRT-D therapy at baseline
were less likely to die at 2 years compared with thoseth Mortality for ICD/CRT-D Therapy
adjusted
dds Ratio
95% CI) p Value
Adjusted
Odds Ratio
(95% CI) p Value
p Value
(Device–Race/
Ethnicity
Interaction)
(0.58–0.74) <0.0001 0.64 (0.52–0.79) 0.0002 0.7861
(0.55–0.77) <0.0001 0.59 (0.46–0.76) <0.0001 —
(0.54–1.03) 0.0717 0.68 (0.42–1.08) 0.1023 0.3558*
(0.55–0.80) <0.0001 0.65 (0.50–0.84) 0.0011 0.5152*
nic white and non-Hispanic black; non-Hispanic white and other race/Hispanic
.
TABLE 4 Rates and Unadjusted and Adjusted Odds Ratios for 24-Month Mortality for ICD-Only Therapy
Subjects
ICD at
Baseline n
Mortality at
24 Months
n (%)
Unadjusted
Odds Ratio
(95% CI) p Value
Adjusted Odds
Ratio (95% CI) p Value
p Value
(Device–Race/
Ethnicity
Interaction)
ICD-only eligible Yes 2,561 518 (20.2) 0.65 (0.57–0.74) <0.0001 0.72 (0.58–0.89) 0.0046 0.8225
No 3,067 852 (27.8)
Non-Hispanic white Yes 1,152 241 (20.9) 0.67 (0.56–0.81) <0.0001 0.68 (0.52–0.90) 0.0075 —
No 1,294 365 (28.2)
Non-Hispanic black Yes 235 50 (21.3) 0.78 (0.53–1.14) 0.2001 0.81 (0.48–1.34) 0.4109 0.3151*
No 294 77 (26.2)
Other race, Hispanic ethnicity,
or not documented
Yes 1,174 227 (19.3) 0.62 (0.52–0.75) <0.0001 0.67 (0.52–0.87) 0.0031 0.9550*
No 1,479 410 (27.7)
*Interaction testing was repeated for subsets of the entire population: non-Hispanic white and non-Hispanic black; non-Hispanic white and other race/Hispanic
ethnicity/undocumented. Variables used for adjustment are noted in the Results section.
Abbreviations as in Tables 1 and 3.
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803without CRT-P/CRT-D (28.8% vs. 38.3%), and on
multivariable analyses, these ﬁndings were also sig-
niﬁcant (adjusted OR: 0.55, 95% CI: 0.33 to 0.91, p ¼
0.0222). Similar to the ICD/CRT-D–eligible cohort and
ICD-only cohort, the device by race/ethnicity inter-
action effect was not signiﬁcant (p ¼ 0.5413). Figure 2
plots the adjusted OR of mortality for device therapy
by race/ethnicity groups.
DISCUSSION
Among the 6,994 patients with HFrEF treated at
outpatient cardiology/multispecialty practices who
were eligible for ICD/CRT-D and 1,023 patients
eligible for CRT-P/CRT-D without crossover, the
clinical beneﬁt associated with ICD or CRT was
substantial. Study patients with device therapy
at baseline had a lower likelihood of death at 24
months compared with those without baseline device
therapy (Central Illustration). Importantly, ICD andTABLE 5 Rates and Unadjusted and Adjusted Odds Ratios for 24-Mon
Subjects
CRT-P/CRT-D
at Baseline n
Mortality at
24 Months,
n (%)
U
O
CRT-P/CRT-D eligible Yes 448 129 (28.8) 0.63
No 575 220 (38.3)
Non-Hispanic white Yes 228 69 (30.3) 0.62
No 278 107 (38.5)
Non-Hispanic black Yes 38 4 (10.5) 0.32
No 55 18 (32.7)
Other race, Hispanic ethnicity,
or not documented
Yes 182 56 (30.8) 0.70
No 242 95 (39.3)
*Interaction testing was repeated for subsets of the entire population: non-Hispanic w
undocumented. Variables used for adjustment are noted in the Results section.
CRT-P ¼ cardiac resynchronization pacemaker; other abbreviations as in Tables 1 andCRT therapy was associated with signiﬁcant survival
beneﬁts overall, and the analyses of device and
race/ethnicity interactions were not statistically sig-
niﬁcant (p ¼ 0.7861 for ICD/CRT-D, p ¼ 0.5413 for
CRT-P/CRT-D), suggesting that the clinical beneﬁt
of device therapy is not driven by race/ethnicity
among outpatients with HF. Although individual
race/ethnicity groups did not meet statistical signiﬁ-
cance, p values for signiﬁcance among subgroups
may not be reliable evidence for lack of beneﬁt,
and interaction testing is preferred for generaliz-
ability (19). In addition, the mortality beneﬁt from
device therapy was not driven by CRT alone, as the
ICD-only analysis yielded a clinically and statistically
signiﬁcant reduction in events. Multivariate analysis
revealed that the mortality beneﬁt of baseline
device therapy persisted after adjusting for baseline
characteristics.
Prior studies have shown mortality beneﬁt for
ICD and CRT therapies, although questions haveth Mortality for CRT-P/CRT-D Therapy
nadjusted
dds Ratio
(95% CI) p Value
Adjusted
Odds Ratio
(95% CI) p Value
p Value
(Device-Race/
Ethnicity
Interaction)
(0.48–0.84) 0.0017 0.55 (0.33–0.91) 0.0222 0.5413
(0.43–0.90) 0.0122 0.63 (0.40–0.99) 0.0435 —
(0.11–0.99) 0.0487 0.35 (0.09–1.36) 0.1306 0.2977*
(0.44–1.13) 0.1444 0.74 (0.42–1.30) 0.2930 0.4549*
hite and non-Hispanic black; non-Hispanic white and other race/Hispanic ethnicity/
3.
Non-Hispanic White
Non-Hispanic Black
Other/Not Documented
Overall
OR LCL UCL
0.59 0.46 0.76
0.68 0.42 1.08
0.65 0.50 0.84
0.64
0.1 101
0.52 0.79
Favors Device Not Favors Device
Device Effect on 24 Month Mortality by Race/Ethnicity in ICD/CRT-D Cohort
Adjusted Odds Ratio and 95% Confidence Interval
Non-Hispanic White
Non-Hispanic Black
Other/Not Documented
Overall
OR LCL UCL
0.68
0.81
0.67
0.72 0.58 0.89
0.52 0.87
0.48 1.34
0.52 090
0.1 101
Favors Device Not Favors Device
Device Effect on 24 Month Mortality by Race/Ethnicity in ICD Only Cohort
Adjusted Odds Ratio and 95% Confidence Interval
Device Effect on 24 Month Mortality by Race/Ethnicity in CRT-P/CRT-D Cohort
Adjusted Odds Ratio and 95% Confidence Interval
Non-Hispanic White
Non-Hispanic Black
Other/Not Documented
Overall
OR LCL UCL
0.63 0.40 0.99
0.35 0.09 1.36
0.74 0.42 1.30
0.55
0.1 101
0.33 0.91
Favors Device Not Favors Device
FIGURE 2 Plots of Adjusted ORs for 24-Month Mortality by Device Type
and Race/Ethnicity
Adjusted odds ratios (ORs) and 95% conﬁdence intervals for 24-month mortality by device
type by each race/ethnic group and overall. LCL ¼ lower conﬁdence limit; UCL ¼ upper
conﬁdence limit; other abbreviations as in Figure 1.
Ziaeian et al. J A C C V O L . 6 4 , N O . 8 , 2 0 1 4
Race/Ethnicity, Device Therapy, and Mortality A U G U S T 2 6 , 2 0 1 4 : 7 9 7 – 8 0 7
804remained as to whether there are differences in
the efﬁcacy and effectiveness of device therapy by
race and ethnicity. In a subgroup analysis of black
patients in the MADIT-CRT (Multicenter Automatic
Deﬁbrillator Implantation Trial–Cardiac Resynchro-
nization Therapy), black patients experienced a
similar magnitude of risk reduction in HF events and
death. In this subgroup analysis, CRT and race did not
contribute a statistically signiﬁcant interaction to
primary outcome, although the primary endpoint
within the race subset was not statistically signiﬁcant
secondary to small sample sizes (Central Illustration).
An analysis of the racial subgroups in the MUSTT
(Multicenter Unsustained Tachycardia Trial) found
that black patients did not do as well when random-
ized to electrophysiologic-guided therapy for ICD
placement, although the number of black patients
in the subgroup analysis was small (n ¼ 61) (20)
(Central Illustration). Similarly, a subgroup analysis
of black patients in the MADIT-II trial was not found
to have a mortality beneﬁt, but was limited by small
patient numbers (n ¼ 102) (21) (Central Illustration). As
previously mentioned, results from the SCD-HeFT
trial, which included 425 black patients, found
similar mortality beneﬁts without evidence that
minorities were less willing to accept device thera-
pies (9). Our ﬁndings are consistent with the SCD-
HeFT subgroup analysis, but provide evidence of
real-world clinical effectiveness. Nevertheless, pri-
ority must be given for future research and clinical
trials to improve the representation of racial and
ethnic minorities to avoid lingering questions
regarding generalizability.
With the expanding evidence base provided by
clinical trials, the number of guideline-recommended
HF therapies has increased. This increase has placed
additional burdens on patients in terms of adherence
and on physicians and health systems in terms
of resource allocation. As racial/ethnic minorities
have historically been under-represented in clinical
trials of CRT/ICD therapy, there are questions
regarding whether this patient population beneﬁts
to a similar degree with device therapy as white pa-
tients. The under-representation of minorities in
clinical trials is a larger issue that likely reﬂects sys-
temic factors rather than patient-speciﬁc factors
(22,23). Although disparities in the use of CRT and ICD
therapy among minorities appears to be diminishing,
these disparities still exist among a proportion of
patients receiving CRT and ICD therapy (24).
To our knowledge, the present study is among
the largest studies to address the question of race/
ethnicity-speciﬁc beneﬁts of ICD or CRT therapies
in real-world clinical practice. Our data support
Study
Device
All Patients
White Patients
Black Patients
Other
Race/Ethnic
Group Patients*
Interaction
Testing P value
MUSTT MADIT II SCD-HeFT MADIT-CRT† IMPROVE HFIMPROVE HF IMPROVE HF
ICD Only 
(EP Guided)
ylnO DCIylnO DCIylnO DCI CRT-D
(vs. ICD Only)
ICD/CRT-D CRT-P/CRT-D
RR 0.40
(0.27-0.59)
HR 0.69
(0.51-0.93)
HR 0.75
(0.55-1.02)
HR 0.73
(0.58-0.90)
HR 0.77
(0.62-0.96)
HR 0.66
(0.52-0.84)
OR 0.64
(0.52-0.79)
OR 0.72
(0.58-0.89)
OR 0.55
(0.33-0.91)
HR 0.60
(0.49-0.73)
OR 0.59
(0.46-0.76)
OR 0.68
(0.52-0.90)
OR 0.63
(0.40-0.99)
HR 1.25
(0.42-3.60)
HR 0.65
(0.43-.99) 
HR 0.78
(0.42-1.46)
OR 0.68
(0.42-1.08)
OR 0.81
(0.48-1.34)
OR 0.35
(0.09-1.36)
OR 0.74
(0.42-1.30)
OR 0.67
(0.52-0.87)
OR 0.65
(0.50-0.84)
N/A 0.39 0.53 0.44 0.79 0.82 0.54
CENTRAL ILLUSTRATION Clinical Outcomes Comparison of Racial/Ethnic Groups With CRT and ICD Therapies
Cardiac resynchronization therapy (CRT) and implantable cardioverter-deﬁbrillator (ICD) therapy has proven to enhance survival in randomized
clinical trials. In the MUSTT (Multicenter Unsustained Tachycardia Trial), black patients (n ¼ 61) did not do as well with electrophysiology
(EP)-guided ICD placement as white patients. Analysis of MADIT II (Multicenter Automatic Deﬁbrillator Implantation Trial) suggested there
were different outcomes with ICD therapy among black (n ¼ 102) and white patients. SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)
showed similar mortality beneﬁt with ICD compared to placebo in black (n ¼ 425) and white patients. MADIT-CRT (Multicenter Automatic
Deﬁbrillator Implantation Trial-Cardiac Resynchronization Therapy) showed no heterogeneity in clinical outcomes for black (n ¼ 143) and white
patients. This new study using data from IMPROVE HF (Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient
Setting) provides evidence of real-world clinical effectiveness with CRT and ICD therapy in patients with heart failure, with no signiﬁcant
heterogeneity in mortality beneﬁts among race/ethnic groups. These ﬁndings suggest device therapy should be offered to all eligible heart
failure patients without consideration of race or ethnicity. Relative risks, hazard ratios, or odds ratios together with 95% conﬁdence intervals are
shown. *Includes patients were race/ethnicity were not documented. †Primary outcome composite of death or HF events. CRT-D ¼ cardiac
resynchronization deﬁbrillator; CRT-P ¼ cardiac resynchronization pacemaker; HR ¼ hazard ratio; OR ¼ odds ratio; RR ¼ risk ratio.
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805the need for race- and ethnicity-speciﬁc outcome
reporting and refute any meaningful differences in
clinical effectiveness as a function of race/ethnicity
for either ICD or CRT-D therapy. These ﬁndings
reinforce current Class I recommendations from the
American College of Cardiology/American Heart As-
sociation HF guidelines that selected HF patients
without racial/ethnic differentiation should, in the
absence of speciﬁc evidence to treat otherwise, have
clinical screening and therapy in a manner identical
to that provided to the broader HF population. Given
the known existence of racial/ethnic disparities in
the use of both CRT and ICD therapies, these data
demonstrating the similarity of beneﬁt elevate to
the highest tier the need to eliminate racial/ethnic
disparities in device-based therapy for HF.
STUDY LIMITATIONS. The design of the IMPROVE
HF registry has some inherent limitations that mayaffect the interpretation of ﬁndings. Speciﬁcally,
patient data were collected by medical chart review,
which is dependent on the accuracy and complete-
ness of documentation. Some patients considered
eligible for treatment who were not treated may have
had contraindications or other reasons that prevented
treatment but were not documented in the medical
record. Although practices were instructed to record
self-assigned race and ethnicity, these characteris-
tics cannot be conﬁrmed, making misclassiﬁcation
possible. The number of patients in race/ethnicity
cohorts other than non-Hispanic white and non-
Hispanic black were too small to analyze indepen-
dently and were included with patients lacking racial/
ethnicity identiﬁcation data. The cohort of other mi-
norities and those lacking racial identiﬁcation may
not reﬂect a readily-identiﬁable patient group in
the literature or practice. In addition, the study had
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: ICDs
and CRT reduce the risks of death and cardiac
arrhythmic events in appropriately-selected patients
with heart failure, but racial/ethnic minorities were
under-represented in the pivotal trials that support
current clinical practice guideline recommendations.
TRANSLATIONAL OUTLOOK: While additional
studies are needed to more clearly deﬁne the genetic,
environmental, and lifestyle factors most closely
associated with the beneﬁt of device-based therapies
for patients with ischemic and nonischemic forms of
advanced cardiac disease, this study suggests that
device therapy should be offered to all eligible heart
failure patients without consideration of race or
ethnicity.
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806only modest power to detect device–race/ethnicity
interactions if they are truly signiﬁcant, and thus,
additional well-powered studies are needed. Patients
receiving devices for secondary prevention, who
are at higher baseline mortality risk, were not distin-
guished and may have biased the results in favor of no
device therapy at baseline. Follow-up on vital status
was not achieved for all patients. This analysis was
conﬁned to patients with complete follow-up
at 24 months, and patients with early crossover to
treatment were excluded from the analysis, which
may have also introduced bias. We did not assess
health-related quality of life, symptom control,
functional capacity, patient satisfaction, hospitaliza-
tion rates, or other clinical outcomes that may be of
interest. As with all observational studies, the possi-
bility for residual measured or unmeasured con-
founding exists, potentially leading to overestimation
or underestimation of treatment effects. The associ-
ations of device use with outcomes do not determine
causality and may reﬂect treatment selection bias. We
could not adjust for socioeconomic factors. The ma-
jority of patients who received CRT received a CRT-D
device, preventing analysis of the association of
CRT-P with outcomes. The guidelines for CRT have
been recently revised and stipulate criteria that differ
in some ways from those in place during the study.
Although patients in the IMPROVE HF registry were
selected from a representative sample from each
practice, enrollment required documented left ven-
tricular function and at least 2 ofﬁce visits with a
cardiologist in the last 2 years, which may have
introduced some ascertainment bias. These ﬁndings
may not apply to practices that differ in patient-case
mix, baseline care patterns, motivation, resources,
and other factors from those that agreed to participate
in the IMPROVE HF registry.
CONCLUSIONS
In this large outpatient cohort of chronic HF pati-
ents treated at cardiology/multispecialty practicesparticipating in a performance improvement initia-
tive, the use of guideline-directed CRT and ICD
therapy was associated with substantially reduced
24-month mortality in eligible HFrEF patients with-
out signiﬁcant interaction by racial/ethnic group. Our
data did not show any meaningful differences
in clinical effectiveness as a function of race/ethnicity
for either ICD or CRT therapy, but additional research
is warranted. These ﬁndings may have important
clinical implications and indicate that CRT-D and ICD
therapies should be offered to all eligible patients
with HFrEF without modiﬁcation based on race/
ethnicity, pending further studies.
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